ASCs, or adipose-derived stem cells, are stem cells found in body fat. They belong to a broader family called mesenchymal stem cells and have the ability to self-renew and transform into multiple types of specialized cells, including bone, cartilage, muscle, fat, and nerve cells. Because fat tissue is abundant and relatively easy to collect, ASCs have become one of the most accessible sources of stem cells in regenerative medicine.
Where ASCs Come From
Fat tissue isn’t just a storage depot for energy. It contains a mix of cell types: mature fat cells, blood vessel cells, immune cells, fibroblasts, and stem cells. ASCs live within this mixture, nestled in the supportive framework of fat tissue rather than inside the fat cells themselves.
To extract ASCs, doctors typically perform a liposuction-like procedure to collect fat, then process it into what’s called the stromal vascular fraction (SVF). This fraction is the non-fat portion of the tissue and contains a cocktail of cell types: stem cells, blood vessel precursors, immune cells, and fibroblasts. ASCs can then be isolated from this fraction and, if needed, grown in the lab to increase their numbers.
There are two main ways to separate the SVF from harvested fat. Enzymatic isolation uses a protein-digesting enzyme to break down the tissue, which yields more cells but is considered more than “minimally manipulated” under U.S. FDA rules. Mechanical isolation physically breaks the tissue apart without enzymes, making it simpler and more acceptable for point-of-care clinical use.
Why ASCs Get So Much Attention
The biggest advantage of ASCs over other stem cell sources is sheer abundance. Bone marrow, the traditional source of mesenchymal stem cells, yields roughly 6 million cells per milliliter of aspirate, but only 0.001% to 0.01% of those are actual stem cells. Fat tissue, by contrast, yields about 2 million cells per gram, and roughly 10% are stem cells. In practical terms, a typical liposuction procedure collecting 1,000 to 2,000 cc of fat can provide 200 to 400 million stem cells, already enough for certain tissue repair applications without weeks of lab expansion. Getting the same number from bone marrow would be far more difficult and uncomfortable for the patient.
ASCs also work through more than one mechanism. They can directly transform into the cell types needed for repair, but they also release a rich mix of signaling molecules: growth factors that promote blood vessel formation, factors that calm inflammation, and chemical signals that recruit other repair cells to the site of injury. This “secretome,” as researchers call it, means ASCs can improve healing even when they don’t physically become the new tissue themselves.
What ASCs Can Become
ASCs are multipotent, meaning they can develop into several (but not all) cell types. The confirmed lineages include:
- Fat cells (adipocytes), useful in reconstructive procedures
- Bone cells (osteoblasts), relevant to fracture healing and bone defects
- Cartilage cells (chondrocytes), of interest for joint repair
- Muscle cells (myocytes), with applications in muscle injury
- Nerve cells (neurocytes), a more experimental but active area of study
- Blood vessel cells, important for tissue survival and wound healing
This versatility is what makes ASCs candidates for such a wide range of medical applications, from orthopedic injuries to chronic wounds to cosmetic procedures.
ASCs in Fat Grafting and Cosmetic Surgery
One of the most established uses of ASCs is in improving fat graft survival during plastic and reconstructive surgery. Fat grafting, where a surgeon transfers fat from one part of your body to another, has long been used for soft-tissue augmentation. The problem is that a significant portion of transplanted fat typically dies and gets reabsorbed, making results unpredictable.
A technique called cell-assisted lipotransfer mixes harvested fat with additional ASCs or SVF cells before injection. In one study, fat grafts enriched with ASCs retained dramatically more volume at four months: 23.0 cubic centimeters compared to just 4.7 cubic centimeters for standard fat grafts. The reason comes down to what happens inside the graft. Only a thin outer zone of transplanted fat, less than 300 micrometers thick, gets enough blood supply for both fat cells and stem cells to survive. In a deeper “regenerating zone,” the mature fat cells die within the first week, but ASCs survive and eventually regenerate new mature fat cells over about three months. More ASCs in the graft means more of it can regenerate rather than simply die off.
ASCs in Wound Healing and Scarring
When skin is injured, ASCs and mature fat cells work together to manage the inflammatory response and regulate how repair cells called fibroblasts behave. ASCs release signaling molecules that can dial inflammation up or down as needed, promote new blood vessel growth, and influence whether a wound heals cleanly or forms excessive scar tissue. This has made ASC-based therapies a focus of research in chronic wounds, burns, and problematic scarring. Even the culture medium that ASCs have been grown in, which contains the full range of molecules they secrete, has shown wound-healing and immune-modulating effects in laboratory studies.
How Scientists Identify ASCs
Under a microscope, ASCs look similar to other mesenchymal stem cells, so researchers identify them using surface proteins. The International Society for Cellular Therapy defines mesenchymal stem cells, including ASCs, by three criteria: they stick to plastic in standard lab culture, they can differentiate into bone, fat, and cartilage cells, and they display a specific pattern of surface markers (positive for CD73, CD90, and CD105; negative for markers associated with blood cells and immune cells).
ASCs also have their own distinguishing features compared to bone marrow stem cells: they tend to be positive for a marker called CD36 and negative for CD106. More recently, researchers screening over 240 surface markers discovered that ASCs from fat under the skin predominantly express a marker called CD10, while ASCs from fat around internal organs predominantly express CD200. These depot-specific markers may eventually help clinicians choose the best source of ASCs for different applications.
Regulatory Status
In the United States, how ASCs are processed determines how they’re regulated. Fat tissue that meets the FDA’s criteria for “minimal manipulation” and “homologous use” (meaning it’s used to perform the same basic function it performed in the body) falls under lighter regulations aimed mainly at preventing disease transmission. It is not regulated as a drug or biologic in that case. However, if the tissue is processed with enzymes or used for a function it didn’t originally perform, it crosses into drug and biologic territory, requiring clinical trials and FDA approval before it can be marketed.
This distinction is why many clinics offering ASC therapies use mechanically processed SVF rather than enzymatically isolated, lab-expanded cells. The regulatory line between the two has been the subject of ongoing legal and scientific debate, with a notable Ninth Circuit court ruling affirming the FDA’s authority to regulate more heavily processed products.